- Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
Cardiovascular Diabetology · 2022
- Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis
Frontiers in Endocrinology · 2022
- The effects of glucagon-like peptide-1 receptor agonists on adipose tissues in patients with type 2 diabetes: A meta-analysis of randomised controlled trials
PLoS ONE · 2022
- New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies
The Journal of Clinical Endocrinology & Metabolism · 2022
- Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy
Diabetes Care · 2022
- Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis
EClinicalMedicine · 2022
- Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
Frontiers in Endocrinology · 2022
- Comparative cardiovascular effectiveness of glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter‐2 inhibitors in patients with type 2 diabetes: A population‐based cohort study
Diabetes Obesity and Metabolism · 2022
- Non‐inferiority and clinical superiority of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes
Diabetes Obesity and Metabolism · 2022
- The time‐varying cardiovascular benefits of glucagon‐like peptide‐1 receptor agonist therapy in patients with type 2 diabetes mellitus: Evidence from large multinational trials
Diabetes Obesity and Metabolism · 2022
- Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
BMC Endocrine Disorders · 2022
- Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis
Diabetes & Metabolism Journal · 2022
- Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis
Frontiers in Endocrinology · 2022
- GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease
Diabetes Care · 2022
- Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease
JAMA Network Open · 2022
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Nature Medicine · 2022
- Effect of glucagon‐like peptide‐1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta‐analysis
Journal of Diabetes Investigation · 2022
- Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular and renal outcomes: A <scp>meta‐analysis</scp> and <scp>meta‐regression</scp> analysis
Diabetes Obesity and Metabolism · 2022
- Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants
The Journal of Clinical Endocrinology & Metabolism · 2022
- Comparative effectiveness of cardiovascular, renal and safety outcomes of second‐line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta‐analysis of randomised controlled trials
Diabetic Medicine · 2021
- The year in cardiovascular medicine 2021: diabetes and metabolic disorders
European Heart Journal · 2021
- Utilization of glucagon‐like peptide‐1 receptor agonists and changes in clinical characteristics in patients with type 2 diabetes by chronic kidney disease stage in Japan: A descriptive observational study using a nationwide electronic medical records database
Diabetes Obesity and Metabolism · 2021
- The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
Cardiovascular Drugs and Therapy · 2021
- The effects of glucagon like peptide-1 (GLP-1) on cardiac remodeling: exploring the role of medication and physiological modulation after metabolic surgery
Minerva Endocrinology · 2021
- Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Expert Review of Clinical Pharmacology · 2021
- Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
Cardiovascular Diabetology · 2021
- GLP‐1 RA and atrial fibrillation in the cardiovascular outcome trials
Diabetes/Metabolism Research and Reviews · 2021
- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
BMJ · 2021
- Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial
Cardiovascular Diabetology · 2021
- Medicaid Expansion and Utilization of Antihyperglycemic Therapies
Diabetes Care · 2020
- Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
Journal of Clinical Pharmacy and Therapeutics · 2020
- Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile
Expert Opinion on Pharmacotherapy · 2020
- Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis
Cardiovascular Diabetology · 2020
- Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
Cardiovascular Diabetology · 2020
- Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
Cardiovascular Diabetology · 2020
- Acupuncture for patients with glucagon-like peptide-1 receptor agonists-induced nausea and vomiting
Medicine · 2020
- PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice
Molecular Metabolism · 2020
- Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study
Diabetes Care · 2020
- Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events
Scandinavian Cardiovascular Journal · 2020
- Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
PLoS ONE · 2020
- Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet
Cardiovascular Diabetology · 2020
- GLP 1 receptor agonists, glycemic variability, oxidative stress and acute coronary syndrome
Medical Hypotheses · 2019
- Review of cardiovascular outcomes trials of sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists
Current Opinion in Cardiology · 2019
- Do GLP‐1RAs and SGLT‐2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta‐analysis
Diabetes Obesity and Metabolism · 2019
- Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
Diabetes Obesity and Metabolism · 2019
- Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis
BMC Pharmacology and Toxicology · 2018
- Cardiovascular Effects of Liraglutide
Current Hypertension Reviews · 2018
- The Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Improves Hypoxia-Induced Pulmonary Hypertension in Mice Partly via Normalization of Reduced ETB Receptor Expression
Physiological Research · 2018
- Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis
Current Diabetes Reviews · 2018
- Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure
Diabetic Medicine · 2018